anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a new compound having tumor necrosis factor production or section inhibitory action, and useful as a therapeutic agent for cachexia, septic shock, multiple organ failure and the like. SOLUTION: This new compound is shown by formula I (R<1> is H, a halogen or the like; R<2> to R<9> are each H, OH or the like, or two groups adjacent to each other among R<6> to R<9> are mutually bound to form, together with the carbon atoms to which they bind, a (substituted) saturated or unsaturated hydrocarbon ring or the like), e.g. 1-(1,2,3,4-tetrahydroisoquionlin-2-yl)phthalazine. The compound of formula I is obtained by reaction of a phtalazine derivative of formula II (X is a halogen) (e.g. 1-chlorophthalazine) with a tetrahydroisoquinoline derivative of formula III (e.g. 1,2,3,4tetrahydroisoquinoline) in an inert organic solvent such as toluene in the presence of a base such as triethylamine at about 0-200 deg.C.
The invention relates to erysipelas lotion. Particularly, the effective components comprise atractylodes rhizome, purple-flower holly leaf, dock root, verdolaga, calcined alum, dahurian patriniae herb, golden thread, cotton rose leaf, zanthoxylum husk, tangkuei tail, largetrifoliolious bugbane rhizome, baical skullcap root, amur corktree bark, erythrina bark, curcuma longa and alkyl silkworm excrement which are reasonably blended, chopped, soaked, decocted, filtered, extracted and condensed to form the erysipelas lotion. The erysipelas lotion can be used for external fumigating treatment for skin and hypodermic acute inflammation erysipelas caused by hemolytic streptococcus. The erysipelas is called as inflammatory disease with redness of skin, erysipelas of the head and filariasis in Chinese medicament. The synergy of the atractylodes rhizome, the purple-flower holly leaf, the dock root, the verdolaga, the calcined alum, the dahurian patriniae herb, the golden thread, the cotton rose leaf, the zanthoxylum husk, the tangkuei tail, the largetrifoliolious bugbane rhizome, the baical skullcap root, the amur corktree bark, the erythrina bark, the curcuma longa and the alkyl silkworm excrement has high-efficient killing effect on pathogenic bacteria, namely hemolytic streptococcus causing the erysipelas. The erysipelas lotion has the efficacies of clearing heat and eliminating dampness, cooling blood and releasing toxin. The erysipelas lotion has the following advantages that: (1) the antibacterial treatment effect is remarkable; (2) the lotion has no stimulation, no corrosion, no injury to the skin and no pollution to the environment; (3) the using concentration is low, and the stability is good; (4) the Chinese medicinal herb type erysipelas lotion is suitable for ages and skin erysipelas treatment; and (5) the process is simple, and the cost is low.
Both parents will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. For the next 6 weeks participants' will receive 4 personalized text messages per week based on their tablet survey responses. Participants will be asked one yes/no question each week ("still breastfeeding? Text Y for yes, N for no"). Once a "no" response has been received from a participant, all remaining text messages will emphasize coping and partner support rather than breastfeeding.
BACKGROUND: Steroid-induced osteonecrosis of the femoral head (SONFH) is a prevalent and incapacitating condition that affects the hip joint. Unfortunately, early diagnostic and treatment measures are limited.
METHODS: Our study employed Tandem Mass Tag (TMT) labeling mass spectrometry (MS)-based quantitative proteome to compare the proteins of femoral head tissues in patients with SONFH with those of patients who sustained femoral neck fracture (FNF). We investigated the level and effects of glucose transporter member 1 (GLUT1) in SONFH patients and MC3T3-E1 cells and examined the function and molecular mechanism of GLUT1 in the context of SONFH using in vivo and in vitro approaches.
RESULTS: The SONFH group exhibited significant changes in protein expression levels compared to the fracture group. Specifically, we observed the up-regulation of 86 proteins and the down-regulation of 138 proteins in the SONFH group. Among the differentially expressed proteins, GLUT1 was down-regulated and associated with glucose metabolic processes in the SONFH group. Further analysis using Parallel Reaction Monitoring (PRM), WB, and PCR confirmed that the protein was significantly down-regulated in both femoral head tissue samples from SONFH patients and dexamethasone-treated MC3T3-E1 cells. Moreover, overexpression of GLUT1 effectively reduced glucocorticoid (GC)-induced apoptosis and the suppression of osteoblast proliferation and osteogenic differentiation in MC3T3-E1 cells, as well as GC-induced femoral head destruction in GC-induced ONFH rat models. Additionally, our research demonstrated that GC down-regulated GLUT1 transcription via glucocorticoid receptors in MC3T3-E1 cells.
CONCLUSIONS: GLUT1 was down-regulated in patients with SONFH; furthermore, down-regulated GLUT1 promoted apoptosis and inhibited osteoblast ossification in dexamethasone-induced MC3T3-E1 cells and contributed to GC-induced femoral head destruction in a SONFH rat model. Glucocorticoids inhibited the transcriptional activity of GLUT1, leading to a reduction in the amount and activity of GLUT1 in the cells and ultimately promoting apoptosis and inhibiting osteoblast ossification via the GC/GR/GLUT1 axis in SONFH.
<P>PROBLEM TO BE SOLVED: To clean a surface with a prion-infected substance by an alkaline cleaning solution, and to remove a protein-like substance from the surface as much as possible.  <P>SOLUTION: The cleaning agent is an alkaline cleaning agent of attacking prion remaining on the surface and of attacking the prion removed from the surface during a cleaning process. A solution of a surfactant, a buffering agent, and a corrosion inhibitor containing no heavy metal is circulated on the surface at 50-60°C, after the cleaning solution is discharged. The surfactant disperses the prion-contaminated substance, and eliminates coagulation. A strong oxidizing agent, preferably a peracetic acid is added at 1,000-2,500 ppm of concentration to the solution. The peracetic acid or the other strong oxidizing agent attacks the prion, in particular, a prion chain released from coagulation, to inactivate the prion. The surface is wrapped with a microbe-impermeable barrier, after rinsed and dried, to be subjected to the final sterilization (for example, a steaming autoclave).  <P>COPYRIGHT: (C)2009,JPO&INPIT
BACKGROUND: The ongoing multi-country mpox outbreak in previously unaffected countries is primarily affecting sexual networks of men who have sex with men. Evidence is needed on the effectiveness of recommended preventive interventions. To inform WHO guidelines, a systematic review and qualitative evidence synthesis were conducted on mpox preventive behavioural interventions to reduce: (i) sexual acquisition; (ii) onward sexual transmission from confirmed/probable cases; and (iii) utility of asymptomatic testing.
METHODS: Medline, EMBASE, PubMed, Cochrane and WHO trial databases, grey literature and conferences were searched for English-language primary research published since 1 January 2022. A reviewer team performed screening, data extraction and bias assessment. A qualitative thematic synthesis explored views and experiences of engagement in prevention in individuals at increased risk.
RESULTS: There were 16 studies: 1 on contact-tracing, 2 on sexual behaviour, and 13 on asymptomatic testing. Although MPXV was detected in varying proportions of samples (0.17%-6.5%), the testing studies provide insufficient evidence to fully evaluate this strategy. For the qualitative evidence synthesis, four studies evaluated the experiences of most affected communities. Preferences about preventive interventions were shaped by: mpox information; the diversity of sexual practices; accessibility and quality of mpox testing and care; and perceived cost to wellbeing.
CONCLUSIONS: Evidence on the effectiveness of interventions to prevent the sexual transmission of mpox remains scarce. Limited qualitative evidence on values and preferences provides insight into factors influencing intervention acceptability. Given global and local inequities in access to vaccines and treatment, further research is needed to establish the effectiveness of additional interventions.
A process, a signal processing unit and to a ventilator automatically calculate a set point for a frequency, with which the ventilator performs ventilation strokes and thereby mechanically ventilates the patient. An alveolar or proximal minute volume is predefined. A lung time constant for the lungs of the patient is determined. The volume of a dead space in a fluid connection between the lungs and the ventilator is determined. A mandatory frequency set point (f set,mand ) for the mandatory ventilation of the patient is calculated. An ideal frequency (f spon ), with which the patient can achieve the minute volume by means of spontaneous breathing, is calculated. The ventilation frequency set point is calculated as a weighted average of the mandatory frequency set point (f set,mand ) and of the ideal frequency (f spon ). The averaging depends on a determined actual intensity of the spontaneous breathing of the patient.
The efficacy of FOSAMAX in men with hypogonadal or idiopathic osteoporosis was demonstrated in two clinical studies.

Daily Dosing

A two-year, double-blind, placebo-controlled, multicenter study of FOSAMAX 10 mg once daily enrolled a total of 241 men between the ages of 31 and 87 (mean, 63). All patients in the trial had either a BMD T-score less than or equal to -2 at the femoral neck and less than or equal to -1 at the lumbar spine, or a baseline osteoporotic fracture and a BMD T-score less than or equal to -1 at the femoral neck. At two years, the mean increases relative to placebo in BMD in men receiving FOSAMAX 10 mg/day were significant at the following sites: lumbar spine, 5.3%; femoral neck, 2.6%; trochanter, 3.1%; and total body, 1.6%. Treatment with FOSAMAX also reduced height loss (FOSAMAX, -0.6 mm vs. placebo, -2.4 mm).

Weekly Dosing

A one-year, double-blind, placebo-controlled, multicenter study of once weekly FOSAMAX 70 mg enrolled a total of 167 men between the ages of 38 and 91 (mean, 66). Patients in the study had either a BMD T-score less than or equal to -2 at the femoral neck and less than or equal to -1 at the lumbar spine, or a BMD T-score less than or equal to -2 at the lumbar spine and less than or equal to -1 at the femoral neck, or a baseline osteoporotic fracture and a BMD T-score less than or equal to -1 at the femoral neck. At one year, the mean increases relative to placebo in BMD in men receiving FOSAMAX 70 mg once weekly were significant at the following sites: lumbar spine, 2.8%; femoral neck, 1.9%; trochanter, 2.0%; and total body, 1.2%. These increases in BMD were similar to those seen at one year in the 10 mg once-daily study.

In both studies, BMD responses were similar regardless of age (greater than or equal to 65 years vs. less than 65 years), gonadal function (baseline testosterone less than 9 ng/dL vs. greater than or equal to 9 ng/dL), or baseline BMD (femoral neck and lumbar spine T-score less than or equal to -2.5 vs. greater than -2.5).
Septo-optic dysplasia is a congenital neurological condition with multifactorial etiology, characterized by septum pellucidum agenesis and/or corpus callosum dysgenesis, hypoplasia of the chiasm or optic nerves, and hormonal dysfunction with pituitary or hypothalamic alterations. Diagnosis requires two of these criteria and magnetic resonance is the imaging test of choice. Most cases present with abnormalities of cortical development in the form known as septo-optic dysplasia plus. While seizures and neurodevelopmental disorders are the dominant neurological manifestations, this entity is highly heterogeneous and has multiple clinical and radiological findings to consider. We present the case of a 35-year-old man with a history of cranioencephalic trauma in childhood and remission for refractory focal epilepsy associated with cognitive deficit. During the initial examination, the simple cranial tomography showed septum pellucidum agenesis and corpus callosum dysgenesis. Brain magnetic resonance imaging revealed agenesis of the septum pellucidum, irregularity and anomalous thickening of the cerebral cortex in frontal lobes and perisylvian region, heterotopic gray matter in frontal lobes and left fronto-insular region, mild supratentorial ventriculomegaly, atypical appearance of the corpus callosum rostrum, and hypoplasia of the chiasm and optic nerves. Although agenesis of the septum pellucidum was the key finding in this case, it is not present in all patients. The relevance of magnetic resonance imaging for the detailed evaluation of other involved structures, highlighting optic nerve hypoplasia, is fundamental in the radiologist's diagnostic workup and this entity recognition.
PURPOSE: Breast cancer is the most frequent cancer in women with significant death rate. Morbidity is associated with drug resistance and metastasis. Development of novel drugs is unmet need. The aim of this study is to show potent anti-neoplastic activity of the UM171 compound on breast cancer cells and its mechanism of action.
METHODS: The inhibitory effect of UM171 on several breast cancer (BC) cell lines was examined using MTT and colony-forming assays. Cell cycle and apoptosis assays were utilized to determine the effect of UM171 on BC cell proliferation and survival. Wound healing scratch and transwell migration assays were used to examine the migration of BC cell lines in culture. Xenograft of mouse model with 4T1 cells was used to determine inhibitory effect of UM171 in vivo. Q-RT-PCR and western blotting were used to determine the expression level of genes effected by UM171. Lentivirus-mediated shRNAs were used to knockdown the expression of KLF2 in BC cells.
RESULTS: UM171 was previously identified as a potent agonist of human hematopoietic stem cell renewal and inhibitor of leukemia. In this study, UM171 was shown to inhibit the growth of multiple breast cancer cell lines in culture. UM171-mediated growth inhibition was associated with the induction of apoptosis, G2/M cell cycle arrest, lower colony-forming capacity, and reduced motility. In a xenotransplantation model of mouse triple-negative breast cancer 4T1 cells injected into syngeneic BALB/c mice, UM171 strongly inhibited tumor growth at a level comparable to control paclitaxel. UM171 increased the expression of the three PIM genes (PIM1-3) in breast cancer cells. Moreover, UM171 strongly induced the expression of the tumor suppressor gene KLF2 and cell cycle inhibitor P21CIP1. Accordingly, knockdown of KLF2 using lentivirus-mediated shRNA significantly attenuated the growth suppressor activity of UM171. As PIM1-3 act as oncogenes and are involved in breast cancer progression, induction of these kinases likely impedes the inhibitory effect of KLF2 induction by UM171. Accordingly, combination of UM171 with a PAN-PIM inhibitor LGH447 significantly reduced tumor growth in culture.
CONCLUSION: These results suggested that UM171 inhibited breast cancer progression in part through activation of KLF2 and P21. Combination of UM171 with a PAN-PIM inhibitor offer a novel therapy for aggressive forms of breast cancer.
PURPOSE:To provide a plaster excellent in adhesivity by locating a primer layer between a filmy support and a water-containing adhesive layer. CONSTITUTION:A primer layer comprising the copolymer of a radically polymerizable monoethylenic unsaturated mono or dicarboxylic acid with an alkyl (meth)acrylate ester is disposed between a filmy support and a water- containing adhesive layer disposed on one side of the filmy support. The filmy support is preferably a flexible film capable of imparting a self-supporting property to the plaster and preventing the evaporation and migration of a medicine in the adhesive layer, and includes a 40-200mum thick ethylene-vinyl acetate copolymer film. The watercontaining adhesive layer is formed from e.g. a polyacrylic acid salt, glycerol, water, aluminum hydroxide, etc. Since skin irritativity is improved by the use of the water-containing adhesive, medicines can be added to the adhesive layer and used as a medical cure plaster for various purposes.
Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.
The Child Sleep Hygiene Questionnaire (CSHQ) and its adapted version for autistic children, known as CSHQ-Autism, have gained recognition as essential tools for studying pediatric sleep patterns. 67 autistic children were evaluated using these questionnaires. 52 children screened positive on the CSHQ while 18 were screened positive on the CSHQ-Autism. Notably, both tools showed elevated ratings in the domains of sleep anxiety and co-sleeping, which may hinder their ability to accurately distinguish sleep disturbances. However, the prevalence of sleep anxiety/co-sleeping in Indian culture was found to be linked to more severe sleep disorders, while also serving as a protective factor against separation anxiety and sudden infant death syndrome (SIDS). Therefore, while the CSHQ and CSHQ-Autism serve as valuable assessment tools, their scores may be inflated by ingrained cultural norms in the Indian context.
AIM: Sexual dysfunction is an important, and often overlooked, sequela of rectal cancer treatment with significant implications for patients' quality of life. The aim of this study was to explore patients' information needs regarding sexual health after rectal cancer treatment and their experiences accessing information on sexual dysfunction throughout the cancer care continuum. The secondary aim was to explore surgeons' perspectives on patients' information needs and gain insight into their experiences providing information on sexual health following rectal cancer surgery.
METHOD: A qualitative study was conducted using semistructured interviews with 10 rectal cancer survivors and six colorectal surgeons from a Canadian tertiary care institution. Transcribed interviews were coded independently by two researchers and thematic analysis was performed.
RESULTS: Analysis of patient interviews revealed that patients had limited knowledge of sexual dysfunction symptoms following rectal cancer treatment and received inadequate information on sexual dysfunction from their treating medical team. Patients expressed the desire to receive information on sexual dysfunction in different formats, especially before the start of treatment. The surgeon interviews revealed that colorectal surgeons faced challenges when informing patients about sexual dysfunction. Surgeons did not routinely provide information on sexual dysfunction to all patients; however, they felt that patients should receive high-quality information on sexual dysfunction, both before and after treatment.
CONCLUSION: Patients' information needs related to sexual dysfunction after rectal cancer treatment were inadequately met. High-quality informational resources are needed to facilitate communication between patients and physicians and improve patients' understanding of sexual dysfunction.
<P>PROBLEM TO BE SOLVED: To provide a means for improving performance, stability and flexibility and using much more time required for data detection for calculating or calculation process.  <P>SOLUTION: A calculation process is decomposed into calculation packets 12-i, and a rule for determining which condition should be satisfied to perform the respective calculation packets (12-i) is defined, whereby an image reconfiguration process is already performed in the midway of detecting the measurement data (MD). Further, the calculation process is reorganized to the progress configuration based upon the calculation packet (12-i) and the rule. Further, the calculation process is synchronized with the detection process and controlled based upon the generated progress configuration. The rule completely describes the calculation process, that is, including all of calculation packets and the logical dependency thereof. Thus, the stability of the calculation process does not completely depends upon the sequence of detecting the measurement data.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz) and cycling stimulation: 40sec On - 02 sec OFF. Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
The present invention provides a inhalation-type pharmaceutical composition for treating lung cancer comprising a first gas and an atomized drug and a preparation method thereof. The first gas contains hydrogen. In the inhalation-type pharmaceutical composition, the volume concentration of hydrogen is 2 to 96%. An atomized drug is selected from a group consisting of cisplatin, docetaxel, etoposide, gefitinib, erlotiniband, and a random combination thereof. The inhalation-type pharmaceutical composition eliminates harmful radical in a patient′s body through usage of hydrogen, and may increase absorption by using the atomized pharmaceutical composition. At the same time, a side effect may be indirectly decreased due to using a small amount of evaporated pharmaceutical fluid.
The present invention relates to a traditional Chinese medicine preparation for treating diabetic heart disease, which takes more than 10 Chinese herbal medicines of motherwort herb, pepperweed seed, agaric, dwarf lilyturf tuber etc. as the raw materials. The present invention has the effects of benefiting qi, nourishing heart, inducing diuresis and removing edema. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine preparation for treating diabetic heart disease. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.